Industry News
Insights into pharmaceutical industry trends and breakthrough technologies
All News
43 articles in total
Site-Specific ADC Conjugation: Chemistry Choices for DAR Control
Site-specific ADC conjugation attaches payloads at defined antibody locations instead of relying on broadly reactive lysine or reduced disulfide chemistry. Site-specific ADC strategies include engineered cysteine, unnatural amino acid, and enzymatic routes as three major ways to control drug-to-antibody ratio (DAR), commonly around 2 or 4. For CHEMOS readers, the practical issue is not only biological design but linker-payload compatibility, hydrophobicity management, reaction sequence, and LC-MS confirmation.
5'-VP Makes GalNAc-siRNA 5'-End Control a Screening Question
5'-(E)-vinylphosphonate, or 5'-VP, is a phosphate mimic placed at the 5' end of an siRNA antisense strand. In the primary ChemBioChem paper cited by the source, the reported response depended on whether a sequence was phosphate-dependent, rather than on GalNAc delivery alone. The practical question for oligonucleotide teams is when to compare 5'-OH, 5'-P, and 5'-VP versions, then track intact strand, terminal identity, total siRNA exposure, and Ago2-associated material where those assays are available.
Antibody-Drug Conjugate Design and Mechanism of Action: Antibody, Linker and Payload
An antibody-drug conjugate (ADC) combines biological targeting with small-molecule potency. The antibody is designed to recognize a tumor-associated antigen. The payload provides the cell-killing or cell-modulating activity. The linker connects the two and controls how stable the conjugate is in circulation and how the payload is released after the ADC reaches the target cell. That simple description hides a complex development problem. ADC performance depends on antigen biology, antibody selection, linker design, payload properties, conjugation site, drug-to-antibody ratio (DAR), formulation and analytical control. A strong ADC program therefore needs coordinated biology and chemistry rather than a payload simply attached to an antibody.
2026 First-Half FDA Novel Drug Approvals: Modality Trends and Chemistry Supply Signals
FDA novel drug approvals are usually discussed from a therapeutic or regulatory perspective. For discovery, CMC and supply-chain teams, the same list also serves as a practical signal: it shows which molecular formats are advancing into real-world development, which types of materials become harder to source, and where chemistry capabilities need to keep pace. By the end of June 2026, the FDA's 2026 novel drug approvals listing included 23 entries. Small molecules remained the largest part of the mix, but the first half of the year also highlighted a broader technical landscape: peptides, fusion proteins, monoclonal antibodies, antibody-drug conjugates, targeted protein degraders and other complex modalities.
RAS Inhibitors as Payloads: ADC vs DAC and the Linker Chemistry Behind Targeted Delivery
RAS has become one of the most important stories in targeted oncology. For decades, RAS proteins were described as "undruggable" because they bind GTP and GDP with high affinity, lack obvious deep binding pockets and sit at the center of multiple growth-factor signaling networks. That view has changed. Structure-guided discovery, covalent chemistry, non-covalent inhibitor design and new concepts such as RAS(ON) multi-selective inhibition have opened a field that once looked closed.
Oligonucleotide Therapeutics Market Trends: Modalities, Delivery Platforms and Supply Chain Opportunities
Oligonucleotide therapeutics have moved from a specialist field into a central part of modern drug discovery. The reason is straightforward: they give drug developers a direct way to modulate genetic information. Instead of looking for a small molecule binding pocket or engineering a large protein-based therapeutic, oligonucleotide drugs can be designed against an RNA sequence, a splice site, a disease-causing transcript or, in some cases, an RNA structure. That design logic has made the field attractive for diseases that were once considered difficult to address with conventional modalities.